Teslascan (mangafodipir)
- Region
- 🇪🇺 EU
- Active substance
- mangafodipir
- Company
- GE Healthcare AS
- Status
- Withdrawn
- Therapeutic area
- Magnetic Resonance Imaging
- EU approval
- Thu 22 May 1997
- Application
- EMEA/H/C/000137
- ATC
- V08CA05
- Official record
- www.ema.europa.eu
Indication
This medicinal product is for diagnostic use only. Contrast medium for diagnostic magnetic resonance imaging (MRI) for the detection of lesions of the liver suspected to be due to metastatic disease or hepatocellular carcinomas. As an adjunct to MRI to aid in the investigation of focal pancreatic lesions.
Regulatory milestones
No milestones recorded in the last year.
Follow Teslascan
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.